Streetbeat News

Analyst Ratings

NVDA

Wolfe Research analyst Chris Caso maintains an Outperform rating on NVIDIA (NASDAQ:NVDA) and raises the price target from $630 to $900.

Portfolio Pulse from Benzinga Newsdesk

February 22, 2024 | 6:20 pm

NVDA

TSLA

Jim Cramer praised Nvidia's CEO, Jensen Huang, as a greater visionary than Tesla's Elon Musk, following Nvidia's strong Q4 earnings. Nvidia's success, driven by demand for its AI chips, contrasts with Tesla's recent underperformance. Cramer highlighted Nvidia's potential for continued growth and its impact on the tech industry.

Portfolio Pulse from Adam Eckert

February 22, 2024 | 6:17 pm

DASH

Financial giants are showing a bullish stance on DoorDash (NASDAQ:DASH) through options trading, with 65% of trades being bullish. The trading activity suggests a target price range of $100 to $165 for DASH in the next three months. DoorDash's current stock price is up 6.59% at $122.25, with analysts giving mixed ratings but an average target price of $134.8. The company has seen significant growth, with a 25% increase in gross order volume and a 31% increase in revenue year over year.

Portfolio Pulse from Benzinga Insights

February 22, 2024 | 6:16 pm

NVDA

HSBC analyst Frank Lee has maintained a Buy rating on NVIDIA (NASDAQ:NVDA) and increased the price target from $835 to $880, indicating a positive outlook on the company's stock.

Portfolio Pulse from Benzinga Newsdesk

February 22, 2024 | 6:11 pm

NVDA

Deutsche Bank analyst Ross Seymore maintains a Hold rating on NVIDIA (NASDAQ:NVDA) and raises the price target from $560 to $720.

Portfolio Pulse from Benzinga Newsdesk

February 22, 2024 | 6:06 pm

SSTK

Morgan Stanley analyst Brian Nowak has initiated coverage on Shutterstock (NYSE:SSTK) with an Equal-Weight rating and set a price target of $55.

Portfolio Pulse from Benzinga Newsdesk

February 22, 2024 | 6:01 pm

BLK

FTNT

JEPQ

SHAK

On CNBC's Halftime Report, analysts shared their final trades, highlighting Shake Shack (SHAK), Fortinet (FTNT), BlackRock (BLK), and JPMorgan Nasdaq Equity Premium Income ETF (JEPQ) as notable picks. These recommendations provide insights into potential stock movements based on the analysts' perspectives.

Portfolio Pulse from Benzinga Newsdesk

February 22, 2024 | 6:01 pm

CCRN

Cross Country Healthcare (NASDAQ:CCRN) has received mixed analyst ratings over the past quarter, with recent evaluations adjusting price targets and ratings due to changing market dynamics and company performance. The average 12-month price target is now $21.25, a 15.0% decrease from the previous $25.00. Analysts from Truist Securities, Benchmark, UBS, and Barrington Research have adjusted their ratings and price targets, reflecting concerns over the company's revenue decline of -30.47% as of September 30, 2023, and operational challenges. Despite this, CCRN's net margin and ROE outperform industry benchmarks, indicating efficient cost management and financial health.

Portfolio Pulse from Benzinga Insights

February 22, 2024 | 6:00 pm

RYTM

Analyst sentiment towards Rhythm Pharmaceuticals (NASDAQ:RYTM) has been predominantly bullish over the past three months, with a notable increase in the 12-month price target to $49.89, reflecting a 26.53% rise from the previous target. The company, engaged in developing therapies for rare diseases, has shown significant revenue growth and a strong market presence, despite challenges in ROE and ROA.

Portfolio Pulse from Benzinga Insights

February 22, 2024 | 6:00 pm

RIVN

JP Morgan analyst Ryan Brinkman downgraded Rivian Automotive (RIVN) from Neutral to Underweight and reduced the price target from $20 to $11, indicating a bearish outlook on the company's stock.

Portfolio Pulse from Benzinga Newsdesk

February 22, 2024 | 5:56 pm